研发中的非青蒿素类抗疟药物综述
该综述汇总2020至2024年MMV项目及临床试验数据库中的16项临床试验,涵盖健康志愿者、实验感染志愿者、无症状恶性疟原虫携带者和疟疾患者,评估多种非青蒿素类候选抗疟药物的安全性、耐受性和疗效。文章指出部分具新作用机制的候选药物正推进临床开发,预计未来十年内许多药物可用于治疗无并发症和重症疟疾,可能显著改善疟疾治疗并减少耐药。
要点
- 16项临床试验评估了MMV533、ZY19489、INE963、GSK701/MMV367、KAE609、cabamiquine/pyronaridine、ganaplacide/lumefantrine-SDF、cipargamin等非青蒿素类候选药物。
- 部分候选药物具新作用机制,正推进临床开发,预计未来十年内可用于无并发症和重症疟疾。
- 新抗疟药可能显著改善疟疾治疗、减少耐药,并支持全球疟疾控制、消除乃至根除目标。
核心结论
- 尽管存在研发失败可能,多种具新作用机制的候选药物正推进临床开发,预计未来十年内许多药物可用于治疗无并发症和重症疟疾。
- 这些新抗疟药可能显著改善疟疾治疗、减少耐药,并支持全球疟疾控制、消除乃至根除目标。
研究设计与样本
- 本综述检索2020至2024年 Medicines for Malaria Venture(MMV)项目及临床试验数据库,共回顾16项临床试验。
- 试验涉及健康志愿者、实验感染志愿者、无症状恶性疟原虫携带者和疟疾患者的安全性、耐受性和疗效研究。
主要发现
- 6项试验在健康志愿者中评估MMV533、ZY19489、INE963、GSK701/MMV367和静脉KAE609的安全性与耐受性。
- 实验感染志愿者疗效试验评估ZY19489和GSK701/MMV367,无症状携带者研究测试ZY19489/ferroquine和cabamiquine/pyronaridine。
- 疟疾患者试验研究ganaplacide/lumefantrine-SDF、cabamiquine/pyronaridine、口服和静脉cipargamin及INE963的组合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2022, malaria caused approximately 249 million cases and 608,000 deaths, primarily in Africa. Current treatments target asexual blood-stage parasites, gametocytes, and liver hypnozoites. Standard guidelines recommend a 3-day course of artemisinin-based combination therapies as a first-line treatment of uncomplicated malaria and parenteral artesunate for severe malaria. However, the emergence of partial resistance to artemisinin derivatives threatens the treatment efficacy, highlighting the urgent need for novel antimalarial drugs. OBJECTIVES: This review summarizes recent progress in the clinical development of antimalarials particularly non-artemisinin compounds under target product profile-1. SOURCES: Data were gathered from Medicines for Malaria Venture (MMV)'s portfolio and clinical trial databases between 2020 and 2024. CONTENT: Sixteen clinical trials were reviewed, including safety and efficacy studies involving healthy volunteers, experimentally infected volunteers, asymptomatic Plasmodium falciparum carriers and malaria patients. Six trials evaluated the safety and tolerability of MMV533, ZY19489, INE963, GSK701/MMV367 and intravenous KAE609 in healthy volunteers. Efficacy trials involving experimentally infected volunteers assessed ZY19489 and GSK701/MMV367, whereas studies on asymptomatic carriers tested ZY19489/ferroquine and cabamiquine/pyronaridine. Trials on malaria patients investigated combinations of ganaplacide/lumefantrine-SDF, cabamiquine/pyronaridine, both oral and intravenous cipargamin and INE963. IMPLICATIONS: Although attrition remains a possibility, several promising candidate drugs with novel modes of action are advancing through clinical development. Many are expected to become available for treating uncomplicated and severe malaria within the next decade. These new antimalarials could significantly enhance malaria treatment, reduce resistance, and support global health efforts towards malaria control, elimination and, potentially, eradication.
引用
- Okwu DG, Zoleko Manego R, Duparc S, et al. The non-artemisinin antimalarial drugs under development: a review. Clin Microbiol Infect. 2025. PMID: 40120754. doi:10.1016/j.cmi.2025.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。